Clinical Trials Logo

Inherited Retinal Dystrophy clinical trials

View clinical trials related to Inherited Retinal Dystrophy.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06212297 Recruiting - Clinical trials for Inherited Retinal Dystrophy

Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

Start date: September 12, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Up to nine subjects who have participated in the earlier LX101 clinical study, and who meet all study eligibility criteria, will receive LX101 administration in the previously uninjected, contralateral eye to evaluate the safety of bilateral, sequential subretinal administration of LX101.

NCT ID: NCT05976139 Recruiting - Macular Edema Clinical Trials

Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies

Start date: September 6, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate whether subthreshold treatment with micropulsed laser can be effective in resolving macular edema in patients with inherited retinal dystrophy. Visits will be performed after 1, 3, 6, 9, 12, 18, and 24 months after treatment. Laser treatment will be performed on the day of the first visit, and its repetition at subsequent visits between months 3 and 12 will be evaluated. Evaluations of treatment effects will include: - comprehensive ophthalmologic examination - multifocal electroretinogram - OCT examination - OCT-angiography examination - retinography Primary endpoint. - central retinal thickness, measured by OCT

NCT ID: NCT05793515 Recruiting - Clinical trials for Retinitis Pigmentosa

Mechanisms of Inherited Retinal Dystrophies Using Whole Genome Sequencing and in Vitro and in Vivo Models

Start date: November 15, 2022
Phase:
Study type: Observational

Inherited retinal dystrophies (IRDs), a large group of heterogeneous and rare disorders, may result in irreversible bilateral visual loss and blindness. Characterizing the genetic bases of IRDs will help to understand the pathogenesis underlying the development of retinal damage. Despite the advances in molecular identification of genes causing disease, unsolved IRDs constitute about 40% of all cases. Goal of this study is to solve missing heritability in IRD using whole genome sequencing (WGS) to identify the genetic causes in clinically well-characterized patients without a molecular diagnosis. The identiļ¬cation of novel genes that have a role in the development or maintenance of retinal function will lead to the development of new therapeutic approaches and will favour a more prompt diagnosis and improvement of patient management.